Protalix BioTherapeutics awarded President and CEO Bashan Dror 480,000 derivative securities on 2026-09-03 at $0 per share. After the transactions, Dror owned 160,000 derivative securities. The figures give PLX investors the reported size of the award, its stated transaction price and the executive’s resulting derivative-securities position.
Key Highlights
- The transactions were recorded at $0 per share on 3 September 2026.
- Bashan Dror owned 160,000 derivative securities after the transactions.
- Bashan Dror is Protalix BioTherapeutics’ president and CEO.
Protalix BioTherapeutics, Inc. (AMEX: PLX) awarded 480,000 derivative securities to Bashan Dror, its president and CEO. The transactions were dated 3 September 2026 and carried a stated price of $0 per share.
480,000 Derivative Securities Awarded The
award covered derivative securities across 2 separate transactions coded A. Bashan Dror was identified in the transaction record as Protalix BioTherapeutics’ president and CEO. The stated price for the securities was $0 per share. The award total was 480,000 derivative securities.
160,000 Securities Held After Transactions Dror
owned 160,000 derivative securities following the transactions. That figure represents the reported post-transaction holding associated with the executive.
FAQs
Q: How many derivative securities did Protalix BioTherapeutics award Bashan Dror?
A: Protalix BioTherapeutics awarded Bashan Dror 480,000 derivative securities. Bashan Dror is the company’s president and CEO. The filing states that the award occurred across 2 separate transactions on 3 September 2026.
Q: What was the price of Bashan Dror’s Protalix securities award?
A: The derivative securities transactions were recorded at $0 per share. They were dated 3 September 2026 and carried transaction code A for both transactions, according to the filing.
Q: How many derivative securities did Bashan Dror own afterward?
A: Bashan Dror owned 160,000 derivative securities after the transactions. The holding figure is reported for the period following the award.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.